Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 162

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 162
---
 Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$669 $200 $468 $(0)$469 $0.32 Non-GAAP adjustments:Amortization expense205 28 177 2 175 0.12 Acquisition/divestiture-related net charges (credits)144 (56)200 — 200 0.13 Restructuring and restructuring-related net charges (credits)52 7 45 — 45 0.03 Investment portfolio net losses (gains) and impairments(1)0 (1)— (1)(0.00)EU MDR implementation costs13 2 12 — 12 0.01 Deferred tax expenses (benefits)— (38)38 — 38 0.03 Adjusted$1,082 $143 $939 $2 $937 $0.63 

41

Table of Contents

Nine Months Ended September 30, 2025

Our net sales for the first nine months of 2025 were $14.788 billion, compared to $12.186 billion for the first nine months of 2024. This increase of $2.602 billion, or 21.4 percent, included operational1 net sales growth of 21.0 percent and the positive impact of 30 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 16.9 percent and the positive impact of 410 basis points from certain acquisitions during the period for which there are less than a full period of comparable net sales. Those acquisitions included the endoluminal vacuum therapy portfolio of B. Braun Medical Inc. (Braun), Silk Road Medical and Axonics during the first, third and fourth quarters of 2024, respectively, and Intera during the second quarter of 2025. The increase in our net sales was primarily driven by strong commercial execution across our businesses, particularly in our Electrophysiology business unit, which was led by the continued growth of our Farapulse™ Pulsed Field Ablation System which launched in the U.S. in early 2024 and in our Watchman business unit, which was led by the adoption of concomitant procedures in the U.S. Refer to Quarterly